Drug intelligence / Profile preview

KN062

Development stage: Discontinued
Lead developer: AlphaMab Oncology
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KN062 is a bispecific neutralizing antibody developed by Alphamab Oncology, through its subsidiary Jiangsu Alphamab, in partnership with Institut Pasteur Shanghai. It was designed for the treatment of COVID-19, leveraging Alphamab's proprietary Mixed Antibodies Platform. The drug advanced to an NDA submission in China but was subsequently discontinued.

Targets

SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)

Beyond the preview

Go deeper on KN062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN062.

Explore the full profile